NASDAQ:GRDX Entero Therapeutics Q1 2026 Earnings Results & Report $4.46 +0.21 (+4.94%) Closing price 04:00 PM EasternExtended Trading$4.59 +0.13 (+2.91%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Entero Therapeutics reported Q1 2026 earnings on May 27, 2026. The company reported EPS of -$0.82, while revenue was $0.04 million. Research:ProfileEarnings History Earnings Announcement Details QuarterQ1 2026Report DateMay 27, 2026TimeBefore Market Opens Entero Therapeutics EPS ResultsActual EPS-$0.82Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEntero Therapeutics Revenue ResultsActual Revenue$0.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Entero Therapeutics Q1 2026 Earnings FAQ Did Entero Therapeutics beat earnings estimates for Q1 2026? Entero Therapeutics (NASDAQ:GRDX) reported earnings of -$0.82 per share for Q1 2026. The report was announced on Wednesday, May 27, 2026. What was Entero Therapeutics' revenue for Q1 2026? Entero Therapeutics reported revenue of $0.04 million for Q1 2026. Entero Therapeutics Earnings HeadlinesNo headlines for this company have been tracked by MarketBeat.com Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email. Email Address About Entero TherapeuticsEntero Therapeutics (NASDAQ:GRDX) is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health. Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure. Entero Therapeutics has also pursued gastrointestinal drug candidates, including locally acting formulations intended to treat inflammatory diseases of the intestines. The company’s activities are primarily focused on research and clinical development rather than the sale of marketed products. Its programs are intended for potential use in gastrointestinal conditions affecting patients in the United States and other international markets, subject to successful clinical development and regulatory approval.View Entero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
